Gain Therapeutics, Inc. Balance Sheet
GANX|4 years of annual SEC 10-K data (FY2021-FY2024)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 4 fiscal years. All figures from audited SEC 10-K filings.
Gain Therapeutics, Inc. had $12M in total assets and $13M in shareholders' equity as of FY2024. Total debt was $328,327 against $10M in cash, resulting in a $10M net cash position.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -16.87 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Cash & Equivalents | $10.4M | $11.8M | $7.3M | $36.9M |
| Current Assets | $11.6M | $17.8M | $21.1M | $37.7M |
| PP&E (Net) | $103.6K | $126.0K | $144.4K | $106.0K |
| Total Assets | $12.1M | $18.6M | $24.1M | $39.0M |
| Current Liabilities | $3.9M | $4.9M | $4.1M | $2.6M |
| Total Debt | $328.3K | $449.1K | $495.3K | $590.5K |
| Shareholders' Equity | $12.6M | $18.9M | $34.8M | $6.2M |